List view / Grid view
17 March 2017 | By F.P.S. Food and Pharma Systems Srl
At Interphex (21-23 March in New York, USA), FPS will show his last innovations in micronization and milling technologies, for pharmaceutical, cosmetic and chemical applications...
17 March 2017 | By Niamh Marriott, Junior Editor
In a new study, advanced metastatic melanoma cancer patients that had become resistant to their BRAF-targeted treatment were given a retreatment...
17 March 2017 | By Niamh Marriott, Junior Editor
AstraZeneca’s Phase III SOLO-2 trial demonstrated a significant improvement in progression-free survival (PFS) in germline BRCA-mutated (gBRCA), platinum-sensitive, relapsed ovarian cancer patients treated with Lynparza (olaparib) tablets (300mg twice daily) compared with placebo in the maintenance setting. The trial met its primary endpoint of investigator assessed PFS (HR 0.30; 95%…
16 March 2017 | By Syrris
Syrris’ state-of-the-art Orb batch reactors are designed by chemists for chemists, ensuring they perfectly meet the demands of your work...
16 March 2017 | By Niamh Marriott, Junior Editor
PharmaJet has partnered with Serum Institute of India to commercialise needle-free delivery of the MMR vaccine using the Stratis 0.5ml needle-free system...
15 March 2017 | By Niamh Marriott, Junior Editor
Patients are set to benefit from more rapid access to the most cost-effective treatments after proposed changes to the NICE drug evaluation process were approved...
15 March 2017 | By Steve Bremer, Managing Editor
Tumour therapy, particularly in the case of multidrug resistant cancers, could be significantly enhanced by using siRNA to down-regulate the production...
15 March 2017 | By Niamh Marriott, Junior Editor
This collaboration is aimed at jointly developing and commercialising new liquid biopsy RAS biomarker tests for metastatic colorectal cancer (mCRC)...
15 March 2017 | By Niamh Marriott, Junior Editor
Moderate-to-severe psoriasis patients treated with Cosentyx (secukinumab) rapidly regain clear skin following relapse during a treatment pause...
14 March 2017 | By Niamh Marriott, Junior Editor
A new health economic analysis of two Phase 3b trials has demonstrated that Novo Nordisk's Tresiba is a cost-effective option for diabetes...
14 March 2017 | By Niamh Marriott, Junior Editor
Sandoz, a Novartis division, presented data for its proposed biosimilar adalimumab, GP2017, showing that their Phase III study met its primary endpoint...
13 March 2017 | By Wickham Labs
Wickham Laboratories Ltd will exhibit on Stand 309 at the Making Pharmaceuticals Conference on the 25th – 26th April 2017...
10 March 2017 | By Steve Bremer, Managing Editor
Representatives from the European Medicines Agency (EMA) met with medicines regulators from Africa last week to discuss how to improve the availability of high quality, safe and effective medicines to patients in countries beyond Europe. One of the tools discussed was the scientific assessment of medicines or vaccines for use…
9 March 2017 | By European Pharmaceutical Review
EFPIA, EBE and IFPMA issue joint guidance for prescribers on switching between original reference biologics and biosimilars...
8 March 2017 | By GBI Research
A substantial number of first-in-class products in the head and neck cancer pipeline will reach the market over the coming decade, which could potentially transform the clinical and commercial landscape, according to business intelligence firm GBI Research.
